δ4-Abiraterone
(Synonyms: 阿比特龙代谢物,Δ4-Abiraterone; CB-7627; Abiraterone D4A metabolite) 目录号 : GC45239An active metabolite of abiraterone
Cas No.:154229-21-7
Sample solution is provided at 25 µL, 10mM.
Quality Control & SDS
- View current batch:
- Purity: >99.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Kinase experiment: | To test D4-abiraterone (D4A) as an inhibitor of 3βHSD, enzyme assays are performed. Briefly, incubations are prepared with recombinant human 3βHSD1 or 3βHSD2 (in yeast microsomes, 45 or 2.5 μg protein per incubation, respectively), D4-abiraterone (5 to 20 μM) or ethanol vehicle in 0.5 mL of potassium phosphate buffer (pH 7.4). After a pre-incubation at 37°C for 1 to 3 min, NAD+ (1 mM) is added, and the incubation is conducted at 37°C for 20 min. The reaction is stopped by addition of 1 mL ethyl acetate:isooctane (1:1), and the steroids are then extracted into the organic phase and dried. The steroids in the dried extracts are resolved by HPLC and quantitated by in-line scintillation counting[1]. |
Cell experiment: | Cells are cultured in serum-free medium for 48 h and then treated with the indicated concentrations of D4-abiraterone (D4A) for 30 min. Cells are washed with 1×PBS four times and 0.9% NaCl solution twice before lysis with RIPA buffer. Intracellular radioactivity is measured with a liquid scintillation counter and normalized to the protein concentration as detected with a Multilabel counter[1]. |
Animal experiment: | Male NSG mice, 6 to 8 weeks of age are used in this study. Mice are surgically orchiectomized and implanted with a 5 mg 90-day sustained-release dehydroepiandrosterone (DHEA) pellet to mimic castration-resistant prostate cancer (CRPC) in the context of human adrenal physiology. Two days later, 107 VCaP or C4-2 cells are injected subcutaneously with matrigel. Once tumours reach 300mm3, mice are arbitrarily (but not strictly randomized) assigned to vehicle (n=9 or 10 mice for VCaP and C4-2 respectively), D4-abiraterone (D4A) (n=10 mice for both cell lines) treatment groups. D4-abiraterone (0.5 mmol per kg per day in 0.1 mL 5% benzyl alcohol and 95% safflower oil solution) is administered via 5 mL per kg intraperitoneal injection every day for up to 15 days. Control groups are administered 0.1 mL 5% benzyl alcohol and 95% safflower oil solution via intraperitoneal injection every day. Tumour volume is measured daily, and time to increase in tumour volume by 20% is determined. Mice are killed at treatment day 15 or when the tumour size is twofold greater than baseline[1]. |
References: [1]. Li Z, et al. Conversion of abiraterone to D4A drives anti-tumour activity in prostate cancer. Nature. 2015 Jul 16;523(7560):347-51. |
D4-abiraterone is a major metabolite of abiraterone. D4-abiraterone is an inhibitor of CYP17A1, 3b-hydroxysteroid dehydrogenase (3βHSD) and steroid-5a-reductase (SRD5A) and also an antagonist of androgen receptor.
D4-abiraterone (D4A ) (10 mM) nearly completely blocks conversion from D4-androstenedione (AD) to 5α-androstanedione and other 5α-reduced androgens. The affinity of D4-abiraterone for mutant (expressed in LNCaP, half-maximum inhibitory concentration (IC50=5.3 nM)) and wild type (expressed in LAPC4, IC50=7.9 nM) androgen receptor (AR) is greater than that of abiraterone (Abi) (IC50=418 and >500 nM, respectively). Compare with Abi, D4-abiraterone clearly better suppresses PSA, TMPRSS2 and FKBP5 expression in LNCAP, LAPC4 and C4-2 cell lines. D4-abiraterone also inhibits AR target gene expression in a dose-dependent manner[1].
D4-abiraterone (D4A) is tenfold more potent than abiraterone (Abi) in blocking conversion from dehydroepiandrosterone (DHEA) by 3β-hydroxysteroid dehydrogenase (3βHSD) to D4-androstenedione (AD) in LNCaP and VCaP xenografts. 0.1 μM D4-abiraterone is equivalent to 1 μM Abi for blocking AD accumulation at 48 h in both LNCaP and VCaP xenografts. Progression is significantly delayed in the D4-abiraterone group compare with the Abi acetate group (P=0.011). D4-abiraterone treatment increases progression-free survival compare with Abi acetate[1].
References:
[1]. Li Z, et al. Conversion of abiraterone to D4A drives anti-tumour activity in prostate cancer. Nature. 2015 Jul 16;523(7560):347-51.
Cas No. | 154229-21-7 | SDF | |
别名 | 阿比特龙代谢物,Δ4-Abiraterone; CB-7627; Abiraterone D4A metabolite | ||
Canonical SMILES | O=C1CC[C@@]2(C)C(CC[C@]3([H])[C@]2([H])CC[C@@]4(C)[C@@]3([H])CC=C4C5=CN=CC=C5)=C1 | ||
分子式 | C24H29NO | 分子量 | 347.5 |
溶解度 | DMSO: 10 mg/ml | 储存条件 | Store at -20°C |
General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。 为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。 |
||
Shipping Condition | 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。 |
制备储备液 | |||
1 mg | 5 mg | 10 mg | |
1 mM | 2.8777 mL | 14.3885 mL | 28.777 mL |
5 mM | 0.5755 mL | 2.8777 mL | 5.7554 mL |
10 mM | 0.2878 mL | 1.4388 mL | 2.8777 mL |
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量) | ||||||||||
给药剂量 | mg/kg | 动物平均体重 | g | 每只动物给药体积 | ul | 动物数量 | 只 | |||
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方) | ||||||||||
% DMSO % % Tween 80 % saline | ||||||||||
计算重置 |
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL saline,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。